New Antidiabetic Drugs for Cardiometabolic Comorbidities in COPD
Cardiometabolic Comorbidities in COPD: Focus on Diabetes, GLP-1 Receptor Agonists, SGLT-2 Inhibitors and Antidiabetic Drugs
Background
COPD (Chronic Obstructive Pulmonary Disease) is a progressive lung disease characterized by persistent airflow limitation, affecting millions globally. Beyond respiratory symptoms, COPD is frequently accompanied by significant cardiometabolic comorbidities, particularly type 2 diabetes mellitus. This coexistence exacerbates disease progression, increases healthcare burden, and significantly impairs patient quality of life. Despite the high prevalence and impact, the optimal therapeutic strategies for managing diabetes in the context of COPD, especially utilizing newer classes of antidiabetic drugs, remain a critical area requiring comprehensive synthesis and review.
Study Design
Population
N=12 RCTs, total n=8,742 T2D patients with comorbid COPD.
Intervention
Newer classes of antidiabetic drugs, including Liraglutide.
Comparator
Older antidiabetic drugs or placebo.
Outcome
Optimal therapeutic strategies for managing diabetes in the context of COPD.